January 11, 2022
1 min read
The FDA has granted investigational drug designation to Ananda Scientific Inc. for Nantheia ATL5, a liquid augmentative cannabidiol-based treatment for opioid use disorder, according to a company press release.
“This is the fourth IND approval for our investigational drug Nantheia product line, and it further reinforces our vision of developing CBD as a therapeutic for a number of key indications,” said Ananda CEO Sohail R. Zaidi.
An upcoming clinical trial for Nantheia ATL5 will take place at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA.
“This clinical study at UCLA is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need,” Zaidi said.
The trial will be funded by the National Institute on Drug Abuse.